대한두경부종양학회지 (Korean Journal of Head & Neck Oncology)

  • 제37권1호
  • /
  • Pages.17-22
  • /
  • 2021
  • /
  • 1229-5183(pISSN)
  • /
  • 2586-2553(eISSN)
대한두경부종양학회 (The Korean Society for Head and Neck Oncology)
권호 표지
DOI QR코드

DOI QR Code

두경부암 환자에서 근치적 방사선치료 후 12주 시행한 양전자방출촬영의 임상적 중요성에 대한 연구

Clinical Significance of FDG PET-CT Scan at 12 Weeks after Curative Radiation Therapy in Patients with Head and Neck Cancer

  • 김영일 (충남대학교 의과대학 방사선종양학과) ;
  • 김준상 (충남대학교 의과대학 방사선종양학과) ;
  • 권진이 (충남대학교 의과대학 방사선종양학과) ;
  • 김섭 (충남대학교 의과대학 방사선종양학과) ;
  • 서영덕 (세종충남대학교병원 핵의학과) ;
  • 구본석 (충남대학교 의과대학 이비인후과교실) ;
  • 장재원 (충남대학교 의과대학 이비인후과교실) ;
  • 조문준 (충남대학교 의과대학 방사선종양학과)
  • Kim, Young-il (Department of Radiation oncology, Chungnam National University Hospital) ;
  • Kim, Jun-sang (Department of Radiation oncology, Chungnam National University Hospital) ;
  • Kwon, Jeanny (Department of Radiation oncology, Chungnam National University Hospital) ;
  • Kim, Sup (Department of Radiation oncology, Chungnam National University Hospital) ;
  • Seo, Youngduk (Department of Nuclear medicine, Chungnam National University Sejong Hospital) ;
  • Koo, Bon-seok (Department of Otolaryngology, Chungnam National University Hospital) ;
  • Chang, Jae-won (Department of Otolaryngology, Chungnam National University Hospital) ;
  • Cho, Moon-June (Department of Radiation oncology, Chungnam National University Hospital)
  • 투고 : 2021.02.03
  • 심사 : 2021.04.08
  • 발행 : 2021.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Objectives: To evaluate clinical significance of FDG PET-CT for detection of residual cancer cells after curative radiation therapy or chemoradiotherapy for patients with squamous cell carcinoma (SCC) of Head and Neck Materials & Methods: A retrospective analysis of patients with SCC of Head and neck with curative radiotherapy or chemoradiotherpy between June 2011 and Jan. 2019 was performed. Sixty patients were treated with Intensity-modulated radiotherapy (IMRT). The Metabolic responses were evaluated on the post-treatment FDG PET-CT at 12 weeks after curative radiotherapy completion. Results: Median follow up was 51.5 months (3-102). The overall survival (OS), disease free survival (DFS), local control rate (LCR), and Distant metastasis free survival (DMFS) at 5 years were 80.5%, 80.1%, 87.7% and 89.1%. Metabolic CR was found in 43 (71.7%) and partial metabolic response (PR) was noted in 17 (14.6%). Metabolic CR was significantly correlated with OS, DFS, LCR, and DMFS. On multivariate analysis, Metabolic CR remained significant for DFS and LCR. Conclusion: Metabolic CR on post-radiotherapy FDG PET-CT is highly predictive of increased DFS and LCR in patients with head and neck cancer.

키워드

참고문헌

  1. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S, et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol. 2013;31:4550-4559. https://doi.org/10.1200/JCO.2013.50.3870
  2. Ong SC, Schoder H, Lee NY, Patel SG, Carlson D, Fury M, et al. Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer. J Nucl Med. 2008;49:532-540. https://doi.org/10.2967/jnumed.107.044792
  3. Sheikhbahaei S, Taghipour M, Ahmad R, Fakhry C, Kiess AP, Chung CH, et al. Diagnostic Accuracy of Follow-Up FDG PET or PET/CT in Patients With Head and Neck Cancer After Definitive Treatment: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2015;205:629-639. https://doi.org/10.2214/AJR.14.14166
  4. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S-150S. https://doi.org/10.2967/jnumed.108.057307
  5. Bonomo P, Cipressi S, Iermano C, Bonucci I, Masi L, Doro R, et al. Salvage stereotactic re-irradiation with CyberKnife for locally recurrent head and neck cancer: a single center experience. Tumori. 2014;100:278-283. https://doi.org/10.1177/1578.17202
  6. Marur S, Forastiere AA. Head and Neck Squamous Cell Carcinoma: Update on Epidemiology, Diagnosis, and Treatment. Mayo Clin Proc. 2016;91:386-396. https://doi.org/10.1016/j.mayocp.2015.12.017
  7. Lavertu P, Adelstein DJ, Saxton JP, Secic M, Wanamaker JR, Eliachar I, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck. 1997;19:559-566. https://doi.org/10.1002/(SICI)1097-0347(199710)19:7<559::AID-HED1>3.0.CO;2-6
  8. Reisser C, Eichhorn K, Herold-Mende C, Born AI, Bannasch P. Expression of facilitative glucose transport proteins during development of squamous cell carcinomas of the head and neck. Int J Cancer. 1999;80:194-198. https://doi.org/10.1002/(SICI)1097-0215(19990118)80:2<194::AID-IJC6>3.0.CO;2-M
  9. Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al. Overexpression of Glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer. 2003;97:1015-1024. https://doi.org/10.1002/cncr.11159
  10. Minn H, Lapela M, Klemi PJ, Grenman R, Leskinen S, Lindholm P, et al. Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. J Nucl Med. 1997;38:1907-1911.
  11. van den Bosch S, Doornaert PAH, Dijkema T, Zwijnenburg EM, Verhoef LCG, Hoeben BAW, et al. (18)F-FDG-PET/CT-based treatment planning for definitive (chemo)radiotherapy in patients with head and neck squamous cell carcinoma improves regional control and survival. Radiother Oncol. 2020;142:107-114. https://doi.org/10.1016/j.radonc.2019.07.025
  12. Morgan R, Chin BB, Lanning R. Feasibility of rapid integrated radiation therapy planning with follow-up FDG PET/CT to improve overall treatment assessment in head and neck cancer. Am J Nucl Med Mol Imaging. 2019;9:24-29.
  13. Brun E, Kjellen E, Tennvall J, Ohlsson T, Sandell A, Perfekt R, et al. FDG PET studies during treatment: prediction of therapy outcome in head and neck squamous cell carcinoma. Head Neck. 2002;24:127-135. https://doi.org/10.1002/hed.10037
  14. de Galiza Barbosa F, Riesterer O, Tanadini-Lang S, Stieb S, Studer G, Pruschy M, et al. Evaluation of 18F-FDG PET/CT as an early imaging biomarker for response monitoring after radiochemotherapy using cetuximab in head and heck squamous cell carcinoma. Head Neck. 2020;42:163-170. https://doi.org/10.1002/hed.25975
  15. Fatehi KS, Thiagarajan S, Dhar H, Purandare N, DCruz AK, Chaukar D, et al. Utility of response assessment PET-CT to predict residual disease in neck nodes: A comparison with the Histopathology. Auris Nasus Larynx. 2019;46:599-604. https://doi.org/10.1016/j.anl.2018.12.009
  16. Kim R, Ock CY, Keam B, Kim TM, Kim JH, Paeng JC, et al. Predictive and prognostic value of PET/CT imaging post-chemoradiotherapy and clinical decision-making consequences in locally advanced head & neck squamous cell carcinoma: a retrospective study. BMC Cancer. 2016;16:116. https://doi.org/10.1186/s12885-016-2147-y